Jan. 4, 2024

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) released its Year in Review, the institute’s top science news of 2023. One review section — Biomedical Imaging Advances — discusses topics including combining ultrasound with artificial intelligence (AI) for cancer detection, an MRI contrast agent that targets hypoxic disease and a helmet with sensors to record brain function.

Also included is an interview between NIBIB and Maryellen Giger, PhD, a professor of radiology at the University of Chicago and the lead contact researcher, about how the Medical Imaging and Data Resource Center (MIDRC) can be used to develop and evaluate AI algorithms. MIDRC has collected images from nearly 55,000 patients, which has helped to create 27 in-house algorithms for the detection, diagnosis, monitoring and prognosis of COVID-19. MIDRC is co-led by investigators from the American College of Radiology® (ACR®), American Association of Physicists in Medicine and the Radiological Society of North America.

The National Institutes of Health (NIH) also recently released its 2023 Research Highlights, divided into three categories: Human Health AdvancesPromising Medical Findings and Basic Research Insights.

ACR will continue to advocate for NIH and biomedical research agencies throughout 2024 to ensure discoveries and research progress.

For more information, contact Katie Grady, ACR Government Affairs Director.


Related ACR News

  • CMS Releases 2026 Medicare Physician Fee Schedule Final Rule

    CMS released the 2026 MPFS final rule Oct. 31. ACR prepared an initial summary about impact on imaging.

    Read more
  • Massachusetts Legislature Updates Prior Authorization Bill

    Massachusetts HB 4616 aims to streamline prior authorization, boost transparency, and study its impact on care access and costs.

    Read more
  • ACR Responds to RFI on AI Regulatory Reform

    ACR urged the White House to enhance AI oversight and payment policies to support safe, effective, and reimbursable clinical AI use.

    Read more